跳至主要内容
临床试验/ISRCTN13607674
ISRCTN13607674已完成2 期

An investigation of the effects of an armband applied over the F11/21 physostigmine and hyoscine transdermal patch on pharmacokinetic, pharmacodynamic and safety profiles in healthy male subjects

Defence Science and Technology Laboratory0 个研究点目标入组 31 人开始时间: 2021年1月11日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
31

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Ability to give written informed consent prior to study participation
  • 2. Healthy Caucasian male subjects aged between 18 and 40 years (inclusive)
  • 3. Body Mass Index (BMI) within the range of =21 and =29 kg/m²
  • 4. Vital signs within the following ranges:
  • 4.1. Heart rate 40 - 90 bpm
  • 4.2. Systolic blood pressure 90 - 140 mmHg
  • 4.3. Diastolic blood pressure 50 - 90 mmHg
  • 5. Ability to communicate well with the Investigator and to comply with the requirements of the study

排除标准

  • 1. Presence of any clinically significant medical condition as determined by the Investigator
  • 2. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug (e.g. renal or
  • liver disease, respiratory, immunological, endocrine or neurological disorders)
  • 3. Any ECG abnormality considered to be clinically significant i.e. baseline prolongation of QT/QTc interval >450 ms or history of additional risk factors for Torsade de Point (heart failure, hypokalemia, family history of Long QT Syndrome)
  • 4. Known or suspected hypersensitivity or idiosyncratic reaction to any of the study products
  • 5. A dibucaine number of less than 70
  • 6. History of asthma (within the previous 10 years), exercise induced bronchospasm or relevant seasonal bronchospasm
  • 7. Lung function of less than 80% of predicted FEV1 and FVC
  • 8. Any history of contact dermatitis
  • 9. Any skin disorder, broken skin, scars, tattoos at the sites of patch application (i.e. on both arms)
  • 10. Glaucoma or a history of glaucoma in first-degree relatives (i.e. parents, siblings or offspring)
  • 11. Presence of Anterior Chamber Narrow Angle (Van Herrick Grade 1 and 2)
  • 12. Intra-ocular pressure exceeding 20 mmHg
  • 13. Uncorrected vision in both eyes of worse than 6/9 on the Snellen Scale
  • 14. Corrected vision of 6/9 or better on the Snellen Scale when wearing +2.25 dioptre reading glasses
  • 15. Required glasses or contact lenses for distance vision
  • 16. History or evidence of drug abuse (opiates, methadone, cocaine, amphetamines, cannabinoids or barbiturates)
  • 17. Positive test for HIV, hepatitis B or hepatitis C
  • 18. History or evidence of alcohol abuse defined as an intake of more than 28 units per week (4 units per day), where 1 unit corresponds to 250 ml beer, 20 ml spirits/liqueur or one glass (100 ml) of wine
  • 19. Positive urine test for alcohol
  • 20. Participation in another clinical study within the last three months
  • 21. Use of any prescription medication within the last 14 days
  • 22. Use of non-prescription medication (apart from paracetamol) within the last seven days that may have an impact on the safety and objectives of the study (at the Investigator’s discretion)
  • 23. Donation of blood or blood products within the last three months, or the intention to donate blood or blood products within three months after completion of the study
  • Baseline (all periods):
  • 1. Development of any exclusion criteria since last visit
  • 2. Positive urine test for alcohol
  • 3. Positive drugs of abuse test
  • 4. Use of any prescription medication since last visit (with the exception of hormonal contraception)
  • 5. Use of non-prescription medication that may impact the safety aspects and objectives of the study, within the last seven days (apart from paracetamol)

研究者

相似试验